• Contcat Us
Saturday, November 21, 2026
Health Buddy
No Result
View All Result
  • Login
  • Register
  • Home
  • National
  • Health
  • Environment
  • Business
  • Govt Bulletin
  • Post-COVID Insights
  • Others
    • Disability
    • Cooperative
    • Science/Tech
    • Lifestyle/Culture
  • Home
  • National
  • Health
  • Environment
  • Business
  • Govt Bulletin
  • Post-COVID Insights
  • Others
    • Disability
    • Cooperative
    • Science/Tech
    • Lifestyle/Culture
No Result
View All Result
Morning News
No Result
View All Result

Alembic Pharma Gets USFDA Nod for Multiple Sclerosis Drug

Alok Uniyal by Alok Uniyal
May 2, 2026
in Exclusive, Health, National, News
0
Alembic Pharma Gets USFDA Nod for Multiple Sclerosis Drug
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

NEW DELHI: Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its generic version of Fingolimod Capsules 0.5 mg, a drug used in the treatment of multiple sclerosis (MS).

The approval allows the company to market the medicine in the United States as a therapeutically equivalent alternative to Gilenya, the branded drug manufactured by Novartis.

READ ALSO

India Develops First Indigenous H5N1 Bird Flu Vaccine

Prez Murmu Stresses One Health Approach To Prevent Future Outbreaks

Fingolimod belongs to a class of medicines known as sphingosine 1-phosphate receptor modulators and is prescribed for patients suffering from relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS and active secondary progressive disease. The treatment is approved for patients aged 10 years and above.

Multiple sclerosis is a chronic neurological disorder in which the body’s immune system attacks the protective covering of nerves, affecting communication between the brain and the body. The disease can lead to symptoms such as muscle weakness, balance problems, fatigue and impaired vision.

According to market research firm IQVIA, the Fingolimod Capsules 0.5 mg market in the United States was estimated at around $145 million for the 12 months ending December 2025.

With this latest clearance, Alembic continues to strengthen its presence in the regulated US generics market. The company now has a cumulative total of 237 approvals from the USFDA, including 219 final approvals and 18 tentative approvals for abbreviated new drug applications (ANDAs).

Founded in 1907, Alembic is among India’s established pharmaceutical companies with a strong presence in branded generics and international markets. The company operates integrated research, development and manufacturing facilities that have received approvals from several global regulatory authorities, including the USFDA.

Headquartered in India, the company markets generic pharmaceutical products across multiple countries and maintains a large domestic presence through a field force of more than 5,500 representatives.

#alembic    #pharma  #india   #fingolimod   #usfda   #novartis  #unitedstates  #fingolimod  #multiplesclerosis

For any query, contact indiahealthbuddy@gmail.com

Related Posts

India Develops First Indigenous H5N1 Bird Flu Vaccine
Health

India Develops First Indigenous H5N1 Bird Flu Vaccine

November 20, 2026
Prez Murmu Stresses One Health Approach To Prevent Future Outbreaks
Health

Prez Murmu Stresses One Health Approach To Prevent Future Outbreaks

November 20, 2026
Centre Pushes Digital Surveillance Against Sex Selection
Health

Centre Pushes Digital Surveillance Against Sex Selection

November 20, 2026
Botswana Cheetah Gives Birth To Four Cubs In India’s Wild
Environment

Botswana Cheetah Gives Birth To Four Cubs In India’s Wild

November 20, 2026
Firecracker Injuries Cross 1,100 In Tamil Nadu, Two Children Killed In Delhi And Odisha
Health

Firecracker Injuries Cross 1,100 In Tamil Nadu, Two Children Killed In Delhi And Odisha

November 9, 2026
New Five-Minute Test May Speed Up Detection Of Haemophilia Complication
Health

New Five-Minute Test May Speed Up Detection Of Haemophilia Complication

November 9, 2026
Next Post
Buddha’s Sacred Relics Return to Ladakh After 75 Years, Amit Shah Calls It a ‘Historic Reunion’

Buddha’s Sacred Relics Return to Ladakh After 75 Years, Amit Shah Calls It a ‘Historic Reunion’

Please login to join discussion

Categories

  • Business
  • Cooperative
  • Culture/Tourism
  • Disability
  • Environment
  • Exclusive
  • Govt Bulletin
  • Health
  • INFODESK
  • Lifestyle
  • MINDFUL CARE: Nourishing Thoughts and Body
  • National
  • News
  • Politics
  • Post-COVID Insights
  • Science
  • Sports
  • Tech

About

We bring you the best Premium WordPress Themes that perfect for news, magazine, personal blog, etc. Check our landing page for details.

Follow us

Other Links

  • Home
  • About Us
  • Editorial Policy
  • BMI Calculator
  • Calorie Counter

Recent Posts

  • India Develops First Indigenous H5N1 Bird Flu Vaccine
  • Prez Murmu Stresses One Health Approach To Prevent Future Outbreaks
  • Centre Pushes Digital Surveillance Against Sex Selection
  • Botswana Cheetah Gives Birth To Four Cubs In India’s Wild

Categories

  • Business
  • Cooperative
  • Culture/Tourism
  • Disability
  • Environment
  • Exclusive
  • Govt Bulletin
  • Health
  • INFODESK
  • Lifestyle
  • MINDFUL CARE: Nourishing Thoughts and Body
  • National
  • News
  • Politics
  • Post-COVID Insights
  • Science
  • Sports
  • Tech
No Result
View All Result
  • Home

© 2025 Essar - Print & IT Solutions Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In